192 related articles for article (PubMed ID: 18782077)
1. Chromatin remodeling agents for cancer therapy.
Dario LS; Rosa MA; Mariela E; Roberto G; Caterina C
Rev Recent Clin Trials; 2008 Sep; 3(3):192-203. PubMed ID: 18782077
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
Teodoridis JM; Strathdee G; Brown R
Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
[TBL] [Abstract][Full Text] [Related]
3. Deregulated chromatin remodeling in the pathobiology of brain tumors.
Spyropoulou A; Piperi C; Adamopoulos C; Papavassiliou AG
Neuromolecular Med; 2013 Mar; 15(1):1-24. PubMed ID: 23114751
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
5. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation.
Nguyen CT; Gonzales FA; Jones PA
Nucleic Acids Res; 2001 Nov; 29(22):4598-606. PubMed ID: 11713309
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells.
Koizume S; Tachibana K; Sekiya T; Hirohashi S; Shiraishi M
Nucleic Acids Res; 2002 Nov; 30(21):4770-80. PubMed ID: 12409468
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells.
Bar-Sela G; Jacobs KM; Gius D
Cancer J; 2007; 13(1):65-9. PubMed ID: 17464248
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
Zahnow CA; Topper M; Stone M; Murray-Stewart T; Li H; Baylin SB; Casero RA
Adv Cancer Res; 2016; 130():55-111. PubMed ID: 27037751
[TBL] [Abstract][Full Text] [Related]
9. Reversal of gene silencing as a therapeutic target for cancer--roles for DNA methylation and its interdigitation with chromatin.
Baylin SB
Novartis Found Symp; 2004; 259():226-33; discussion 234-7, 285-8. PubMed ID: 15171257
[TBL] [Abstract][Full Text] [Related]
10. CpG-island methylation and epigenetic control of resistance to chemotherapy.
Teodoridis JM; Strathdee G; Plumb JA; Brown R
Biochem Soc Trans; 2004 Dec; 32(Pt 6):916-7. PubMed ID: 15506923
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy.
Worm J; Guldberg P
J Oral Pathol Med; 2002 Sep; 31(8):443-9. PubMed ID: 12220350
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
14. Chromium cross-links histone deacetylase 1-DNA methyltransferase 1 complexes to chromatin, inhibiting histone-remodeling marks critical for transcriptional activation.
Schnekenburger M; Talaska G; Puga A
Mol Cell Biol; 2007 Oct; 27(20):7089-101. PubMed ID: 17682057
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic mechanism of rRNA gene silencing: temporal order of NoRC-mediated histone modification, chromatin remodeling, and DNA methylation.
Santoro R; Grummt I
Mol Cell Biol; 2005 Apr; 25(7):2539-46. PubMed ID: 15767661
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
Herranz M; Esteller M
Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
[TBL] [Abstract][Full Text] [Related]
17. Reactivating the expression of methylation silenced genes in human cancer.
Karpf AR; Jones DA
Oncogene; 2002 Aug; 21(35):5496-503. PubMed ID: 12154410
[TBL] [Abstract][Full Text] [Related]
18. [Chromatin epigenetic modifications in cancer generation].
Arenas-Huertero F; Recillas-Targa F
Gac Med Mex; 2002; 138(6):547-55. PubMed ID: 12532619
[TBL] [Abstract][Full Text] [Related]
19. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression.
Claus R; Fliegauf M; Stock M; Duque JA; Kolanczyk M; Lübbert M
J Leukoc Biol; 2006 Dec; 80(6):1462-72. PubMed ID: 17000900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
